Clinical trials: fludarabine phosphate
- Drug or intervention fludarabine phosphate
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
This study has 2 parts: Phase 1A and Phase 1B. The primary objectives of Phase 1A are to evaluate the safety of KITE-439 and to determine a recommended Phase 1B dose.
- Trial name
- NCT03912831
- Testing
- KITE-439, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- Gilead Sciences
Neoplasms
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.
- Trial name
- NCT04526509
- Testing
- GSK3901961, GSK3845097, GSK4427296
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 12 people
- Sponsor
- Adaptimmune
Lymphocytic Leukemia, Chronic
A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)
This open-label, 2-arm, nonrandomized, multicenter, Phase Ib study will investigate the safety and efficacy of obinutuzumab (RO5072759; GA101) administered in combination with chemotherapy (bendamustine or fludarabine +…
- Trial name
- NCT01300247
- Testing
- Fludarabine, Obinutuzumab, Bendamustine
- Where
- 18 sites in United States
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
This is an open-label, multicenter, Phase 1/2 study to determine the safety and efficacy of JCARH125, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple…
- Trial name
- EVOLVE (NCT03430011)
- Testing
- JCARH125, JCARH125 + anakinra
- Where
- 20 sites in United States
- Volunteers
- 165 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
The purpose of this study is to test the safety and efficacy of AUTO4 a chimeric antigen receptor (CAR) T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive selected T-Non-Hodgkin Lymphoma (NHL).
- Conditions
- T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT03590574
- Testing
- AUTO4
- Where
- 5 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Autolus Limited
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.
- Trial name
- NCT02013167
- Testing
- Blinatumomab, Standard of Care Chemotherapy
- Where
- 117 sites in United States, Australia and 19 more
- Volunteers
- 405 people
- Sponsor
- Amgen
Chronic Lymphocytic Leukemia
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic…
- Trial name
- NCT01905943
- Testing
- Bendamustine, Chlorambucil, Cyclophosphamide
- Where
- 174 sites in Argentina, Belgium and 29 more
- Volunteers
- 979 people
- Sponsor
- Hoffmann-La Roche
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
- Trial name
- NCT02626338
- Testing
- Crenolanib, Mitoxantrone, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Lymphoma, Non-Hodgkin
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
This is a single-arm, single institution, phase II study of fludarabine monophosphate followed by Iodine I 131 Tositumomab for patients with previously untreated, advanced-stage (stage III or IV) low-grade, transformed low-grade…
- Trial name
- NCT00933335
- Testing
- Tositumomab and Iodine I 131 Tositumomab
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Lymphocytic Leukemia, Chronic
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
This study will evaluate the efficacy and safety of rituximab in combination with chemotherapy (fludarabine and cyclophosphamide) in participants with B-cell CLL.
- Trial name
- NCT02533401
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 9 sites in Argentina, Venezuela
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia, Multiple Myeloma
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
- Trial name
- NCT04097301
- Testing
- MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
- Where
- 3 sites in Czechia, Italy
- Volunteers
- 8 people
- Sponsor
- AGC Biologics S.p.A.
Chronic Lymphocytic Leukemia (CLL)
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a…
- Trial name
- CRISTALLO (NCT04285567)
- Testing
- Obinutuzumab, Venetoclax, Fludarabine
- Where
- 40 sites in United States, Australia and 3 more
- Volunteers
- 166 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of GSK3845097 in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive participants with New York esophageal squamous cell carcinoma (NY-ESO)-1…
- Trial name
- NCT05943990
- Testing
- GSK3845097, Cyclophosphamide, Fludarabine
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 5 people
- Sponsor
- Adaptimmune
AML
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication…
- Trial name
- NCT02039726
- Testing
- Quizartinib, Salvage Chemotherapy
- Where
- 131 sites in United States, Australia and 17 more
- Volunteers
- 367 people
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
- Trial name
- NCT04789408
- Testing
- Cyclophosphamide, Fludarabine, KITE-222
- Where
- 9 sites in United States, France
- Volunteers
- 15 people
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
- Trial name
- ZUMA-3 (NCT02614066)
- Testing
- brexucabtagene autoleucel, Cyclophosphamide, Fludarabine
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 125 people
- Sponsor
- Kite, A Gilead Company
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Trial name
- NCT04029688
- Testing
- Idasanutlin, Venetoclax, Cyclophosphamide
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Hematologic Malignancies, Acute Myeloid Leukemia
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
This study is a Phase 1, non-randomized, open-label/Phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic…
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT02743351
- Testing
- ProTmune, Control Arm
- Where
- 15 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fate Therapeutics
Neoplasms
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.
- Trial name
- NCT02588612
- Testing
- letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Leukaemia, Lymphocytic, Chronic
Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia
The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT00824265
- Testing
- OFC Infusion, FC infusion
- Where
- 135 sites in United States, Brazil and 16 more
- Volunteers
- 365 people
- Sponsor
- Novartis Pharmaceuticals